Equity Research Biotechnology

Should You Buy MapLight Therapeutics, Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 0/13 models active

According to the CirclFi Deep Alpha Valuation Engine, MapLight Therapeutics, Inc. (MPLT) presents a moderate quality profile with a QOC score of 4.8/10. Trading at $12.08, separating genuine undervalued opportunities from value traps is essential, as detailed by our model data.

The short answer: 0 of 0 CirclFi valuation models project upside for MapLight Therapeutics, Inc. (MPLT) at $12.08 — the models are evenly split, with a Quality Score of 4.8/10 and Value-Trap risk of 27/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • Models are split: 0 bullish vs 0 bearish
  • Quality Score: 4.8/10 — Weak — below-average fundamentals
  • Value Trap Risk: 27/100 — Low — manageable risk
  • Fair Value Range: — – —

Bullish Models

0 / 0

Bearish Models

0 / 0

Quality Score

4.8 /10

Weak — below-average fundamentals

Value Trap Risk

27 /100
Low

Low — manageable risk

Model Consensus

0 /13
Active Models

Full institutional coverage

What Is the Investment Case for MapLight Therapeutics, Inc. (MPLT) in 2026?

What Is the Bull Case vs the Bear Case for MapLight Therapeutics, Inc. (MPLT)?

Bull case versus bear case for MapLight Therapeutics, Inc. (MPLT) at $12.08, derived from 0 active CirclFi valuation models on 2026-09-15.
Bull case Bear case
No active model projects meaningful upside for MPLT at $12.08. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. No active model flags significant downside for MPLT. The low Value Trap score paints a constructive picture.

How Does MPLT Compare to Its Biotechnology Peers?

DFTX Definium Therapeutic
4.9
DMRA Damora Therapeutics,
4.8
PLRX Pliant Therapeutics,
4.9
NNVC NanoViricides, Inc.
4.8
PGEN Precigen, Inc.
4.9
RAPP Rapport Therapeutics
4.8
CNTN Canton Strategic Hol
4.2
ARVN Arvinas, Inc.
7.2

Valuation data pages: DFTX · DMRA · PLRX · NNVC · PGEN · RAPP · CNTN · ARVN · ROIV · EXEL · INCY

See full Biotechnology rankings →

Which Other Stocks Score Like MPLT on Quality?

Closest companies to MPLT’s Quality of Company score of 4.8/10, across all industries.

Which Biotechnology Screens Does MPLT Appear In?

Why Do CirclFi’s 0 Models Disagree on MPLT?

What Are the Biggest Risks of Buying MPLT Stock?

Weak Fundamentals

QOC 4.8/10 signals below-average quality.

Macro/Sector Risk

Biotechnology headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View MPLT Data Page →

So Is MapLight Therapeutics, Inc. (MPLT) Worth Buying in 2026?

MapLight Therapeutics, Inc. currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.

These are quantitative model outputs, not investment recommendations. MapLight Therapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About MPLT Stock?

Should I buy MPLT stock right now?

Based on CirclFi's multi-model analysis, 0 of 0 models see upside for MPLT at $12.08. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in MapLight Therapeutics, Inc.?

Key risks include: a below-average Quality Score of 4.8/10, indicating fundamental weakness; limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.

How does MPLT compare to its competitors?

Among Biotechnology peers, MPLT holds a Quality Score of 4.8/10. Comparable companies include DFTX (QOC 4.9), DMRA (QOC 4.8), PLRX (QOC 4.9). The relative ranking helps investors identify whether MPLT offers better fundamental quality than alternatives in the same sector.

Is MPLT a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. MPLT's Quality Score of 4.8/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy MPLT at?

CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for MPLT.

View MPLT Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →